Document:

Exhibit
10.4

 

AMENDMENT
NO. 2 TO ASSET PURCHASE AGREEMENT

 

This
Amendment No. 2 dated August 4, 2014 (this “Amendment”) is to the Asset Purchase Agreement, dated as of June
30, 2014, entered into by and among Stryker Corporation, a Michigan corporation (“Stryker”), Stryker Biotech
L.L.C., a Michigan limited liability company (“Seller”), and Mariel Therapeutics, Inc., a Delaware corporation
(“Purchaser”) (the “Asset Purchase Agreement”). Seller, Stryker and Purchaser are herein
referred to individually as a “Party” and collectively as the “Parties.” All terms used,
but not defined, herein shall have the respective meanings set forth in the Asset Purchase Agreement.

 

WHEREAS,
at the Closing, Purchaser delivered to Seller the Secured Promissory Note (the “Note”) in lieu of the payment
of the first $500,000 of the Upfront Purchase Price;

 

WHEREAS,
on July 14, 2014 an Event of Default occurred under Section 5(a) of the Note as a result of the failure of Purchaser to
pay the outstanding principal of and interest due and payable under the Note on the maturity date (July 14, 2014), and the Parties
amended and restated the Note to extend the maturity date thereof to July 31, 2014 (“Maturity Date”) in consideration
for an acceleration of a certain portion of the second Upfront Purchase Price payment under Section 2.04(a)(iii) of the Asset
Purchase Agreement (the Note, as amended and restated, the “A&R Note”);

 

WHEREAS,
on July 31, 2014 an Event of Default occurred under Section 5(a) of the A&R Note as a result of the failure of Purchaser
to pay the outstanding principal of and interest due and payable under the A&R Note on the Maturity Date; and

 

WHEREAS,
the Parties have agreed to further amend the Asset Purchase Agreement to extend the payment date of that certain portion of the
Upfront Purchase Price payment under Section 2.04(a)(iii) of the Asset Purchase Agreement in consideration for Joseph Hernandez’s
personal guaranty of such payment.

 

NOW,
THEREFORE, Purchaser, Seller and Stryker desire to amend Asset Purchase Agreement in certain respects as set forth below and
the Asset Purchase Agreement is hereby amended as follows:

 

1.1             
Section 2.04(a) of the Asset Purchase Agreement shall be amended by deleting such subsection in its entirely and replacing
it with the following:

 

(a)               
Upfront Purchase Price. The upfront purchase price for the Purchased Assets shall be $1,500,000 (the “Upfront
Purchase Price”), (i) $500,000 of which shall be paid by Purchaser to Seller at the Closing by the Secured Promissory
Note, (ii) $100,000 of which shall be held back by Purchaser and shall be released and paid to Seller on or before August 8, 2014,
the amount of which shall be personally guaranteed by Joseph Hernandez pursuant to the Personal Guaranty in the form attached
hereto as Exhibit A, (iii) $400,000 of which shall be held back by Purchaser and shall be released and paid to Seller within
thirty (30) days after the Technology Transfer Completion Date provided that Seller has delivered to Purchaser the thirteen
(13) one-liter bottles containing the 2010 lot of serum-free BMP-7 protein (the “Serum Free Assets”)
and (iv) $500,000 of which shall be held back by Purchaser and shall be released and paid to Seller on the earlier of (x) December
31, 2014 or (y) the completion of an initial

    	 	1	 

     

    

public
offering of Purchaser’s securities. For the avoidance of doubt, no payment shall be due to Seller pursuant to Section
2.04(a)(iii), unless Seller has delivered the Serum Free Assets to Purchaser. The Upfront Purchase Price shall be non-refundable
and non-creditable, except as set forth in Section 7.

 

1.2             
If any provision of this Amendment, as applied to any of the Parties or to any circumstance, is declared by a Court of competent
jurisdiction to be illegal, unenforceable or void, this Amendment will continue in full force and effect without said provision.

 

1.3             
Purchaser has requested that Stryker and Seller consent to Purchaser’s engagement of Ropes & Gray LLP in connection
with prosecution of patents acquired in connection with the Asset Purchase Agreement as well as other matters. Purchaser hereby
acknowledges that Ropes & Gray LLP is counsel to Stryker and Seller in connection with the Asset Purchase Agreement and that
this representation is adverse to Purchaser. Purchaser agrees that Ropes & Gray LLP may continue to represent Stryker and
Seller in connection with the Asset Purchase Agreement, including as counsel to Stryker and Seller in litigation against Purchaser
in connection with the Asset Purchase Agreement. Purchaser acknowledges and agrees that if, notwithstanding Purchaser’s
consent hereunder, Ropes & Gray LLP determines in its sole discretion that at any time or for any reason that it cannot represent
both Stryker and Seller, on the one hand, and Purchaser, on the other hand, that it may withdraw from representation of Purchaser
and continue to represent Stryker and Seller, including in connection with any litigation by Stryker and Seller against Purchaser.
Based on the foregoing agreement by Purchaser, Stryker and Seller hereby consent to Purchaser’s engagement of Ropes &
Gray LLP on terms otherwise acceptable to Ropes & Gray LLP.

 

1.4             
Except as otherwise expressly modified by this Amendment, all terms and provisions of the Asset Purchase Agreement shall remain
in full force and effect.

 

1.5             
All references to the Asset Purchase Agreement shall hereinafter be deemed to be references to the Asset Purchase Agreement as
amended by this Amendment.

 

1.6             
This Amendment may be signed in any number of counterparts, including by facsimile copies or by electronic scan copies delivered
by Email, each of which will be deemed an original, with the same effect as if the signatures were upon the same instrument.

 

 

[Remainder
of the page intentionally left blank; signature page follows]

    	 	2	 

     

    

IN
 WITNESS  WHEREOF,  each  of the  Parties  has  caused  this  Amendment  to  be executed on its behalf by its respective duly
authorized officer as of the date first set forth above.

  

	Stryker
                            Corporation

                             

                            By:
                            /s/ Scott Bruder

                            Name:
                            Scott Bruder, MD, Ph.D.

                            Title:
                            Chief Medical and Scientific Officer

	 
	Stryker
        Biotech L. L. C.

         

        By:
        /s/ James Kemler

        Name:
        James Kemler

        Title:
        Chief Executive Officer

	 
	Mariel Therapeutics, Inc.

    

    By: /s/ Joseph Hernandez

    Name: Joseph Hernandez

    Title: Executive Chairman

 

[Signature
Page to Amendment No. 2 to Asset Purchase Agreement]

    	 	3	 

     

    

EXHIBIT
A

 

Personal
Guaranty

    	 	4	 

     

    

PERSONAL
GUARANTY 

 

In
consideration of Stryker Biotech L.L.C.’s forbearance and extension of the time for payment of distributions pursuant to
the Asset Purchase Agreement, dated as of June 30, 2014, as amended by (i) Amendment No. 1 to Asset Purchase Agreement, dated
July 18, 2014, and (ii) Amendment No. 2 to Asset Purchase Agreement, dated August [ ], 2014 (as such agreement may be amended,
restated and/or modified from time to time, the “Asset Purchase Agreement”) between Stryker Corporation, Stryker
Biotech L.L.C. (“Seller”) and Mariel Therapeutics, Inc. (the “Purchaser”) and in respect
of other consideration, the receipt and sufficiency of which are hereby acknowledged;

 

I,
Joseph Hernandez (the “Guarantor”) hereby unconditionally guarantee (the “Guaranty”) to
Seller, upon the terms and conditions hereinafter provided, the prompt payment when due of $100,000 required to be paid by Purchaser
to Seller pursuant to Section 2.4(a)(ii) of the Asset Purchase Agreement (the “Guaranteed Obligations”). In
the event that the Guaranteed Obligations are not timely paid in full, Guarantor acknowledges and agrees that (i) any payments
by Purchaser thereafter to Seller or (ii) collections from collateral securing the Secured Promissory Note shall be credited,
first, to payment of Secured Obligations (as defined in the Secured Promissory Note) other than the Guaranteed Obligations, and,
second, to the Guaranteed Obligations.

 

1.                    
Renewal or Extension. This Guaranty shall continue to be effective notwithstanding any renewal or extension of time of
payment hereunder.

 

2.                    
Nature of Guaranty. This Guaranty is a guarantee of payment and not of collectability. My liability hereunder is absolute,
independent and unconditional. In the event of default in payment by me under the Guaranteed Obligations, my liability hereunder
shall constitute an immediate, direct and primary obligation and shall not be contingent upon Seller’s exercise or enforcement
of any remedy available against me or any other person.

 

3.                    
Governing Law. This Guaranty shall be governed by, and construed in accordance with, the laws of the State of New York.
All Actions arising out of or relating to this Guaranty shall be heard and determined exclusively in the United States District
Court for the District of New York; provided, however, that if such federal court does not have jurisdiction over
such Action, such Action shall be heard and determined exclusively in any New York state court. Consistent with the preceding
sentence, the parties hereby (a) submit to the exclusive jurisdiction of any federal or state court sitting in New York for the
purpose of any Action arising out of or relating to this Guaranty brought by any party hereto and (b) irrevocably waive, and agree
not to assert by way of motion, defense, or otherwise, in any such Action, any claim that it is not subject personally to the
jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the Action is
brought in an inconvenient forum, that the venue of the Action is improper, or that this Guaranty or the transactions contemplated
by this Guaranty may not be enforced in or by any of the above-named courts. For the purposes of this Section 3, “Action”
means any claim, cause of action, suit, arbitration, complaint, criminal prosecution, demand, summons, citation, notice of violation,
governmental

    	 	5	 

     

    

or
other proceeding or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or equity.

 

4.                    
Term. This Guaranty shall continue until the Guaranteed Obligations have been paid in full.

 

5.                    
Waiver. Waiver by Seller of any breach of this Guaranty or the failure of Seller to exercise any right hereunder, or any
right contained in any instrument relating to an obligation guaranteed hereunder, shall not be deemed to be a waiver of any breach
or right. The failure of any party to take action by reason of any such breach or to exercise any such right, shall not deprive
such party of the right to take action at any time while such breach, or conditions giving rise to such right, continues or recurs.

 

6.                    
Written Waiver. No waiver or modification of this Guaranty, or any covenant, condition or limitation herein contained,
shall be valid, unless in writing and duly executed by Seller.

 

7.                    
Severability. All agreements and covenants contained herein are severable, and in the event of any of them shall be held
to be invalid by any competent court, this contract shall be interpreted as if such invalid agreements or covenants were not contained
herein.

 

8.                    
Additional Terms. All terms herein shall have the same meaning as provided of in the Asset Purchase Agreement and I agree
to be bound by the terms of the Guaranteed Obligations as if set out here in full.

 

 

[Signature
page follows]

    	 	6	 

     

    

IN
 WITNESS  WHEREOF,  intending  to  be  bound,  the  undersigned  Guarantor  has executed this Guaranty as of this 4th day
of August, 2014.

 

Print
Name: Joseph Hernandez

  

 /s/
Joseph Hernandez

  

Accepted
and agreed: 

 

STRYKER
CORPORATION

 

 

Signature:
 /s/ Scott Bruder

By:Scott
Bruder, MD, Ph.D.

Title:
 Chief Medical and Scientific Officer

 

 

STRYKER
BIOTECH L.L.C.

 

 

Signature:
 /s/ James Kemler

By:James
Kemler

Title:
Chief Executive Officer

 

[Signature
Page to the Guarantee]

    	 	7Exhibit
                                         10.5 

 

MARIEL
THERAPEUTICS, INC.

 

Second
Amended and Restated Secured Promissory Note

 

	$1,013,216.44	August
    3, 2015

 

Subject
to the terms and conditions of this Second Amended and Restated Secured Promissory Note (this “Note”), for
value received, Mariel Therapeutics, Inc., a Delaware corporation (the “Company”) and Ember Therapeutics, Inc.
(“Ember”), jointly and severally, promise to pay to the order of Stryker Biotech L.L.C., a Michigan limited
liability company, for itself and as agent for Stryker Corporation (the “Holder”), the principal amount of
One Million Thirteen Thousand Two Hundred Sixteen Dollars and Forty Four Cents ($1,013,216.44), together with interest accrued
from the date of issuance of this Note on the unpaid principal balance at the rate of eight percent (8%) per annum computed on
the basis of the actual number of days elapsed and a year of 365 days. This Note shall be due and payable on the earlier of (i)
the Maturity Date (as defined in Section 2, below) and (ii) following an Event of Default (as defined in Section 6,
below), on any accelerated maturity date as provided in Section 7 below. This Note is issued in connection with that Second
Personal Guaranty Agreement by and among Yosbani Joseph Hernandez (“Guarantor”), Holder and Stryker Corp. and
that Security Agreement by and among Guarantor, Holder and Stryker Corp., each dated as of the date hereof.

 

1.  Amendment
and Restatement. This Note (i) amends and restates the Amended and Restated Secured Promissory Note of the Company dated June
30, 2014 (the “Prior Note”), which is cancelled by renewal, and (ii) incorporates (x) amounts due under Section
2.04(a)(iii) of that certain Asset Purchase Agreement dated June 30, 2014 (the “Asset Purchase Agreement”)
by and among the Company, the Holder and Stryker Corporation (“Stryker Corp.”) and (y) interest accrued through
the date hereof in respect of amounts due under the Prior Note and Section 2.05(e)(vii) of the Asset Purchase Agreement.

 

2.  Maturity
Date. The outstanding principal amount of the Note and any accrued but unpaid interest thereon shall be due and payable by
11:59PM Eastern Standard Time on August 3, 2016 (the “Maturity Date”).

 

3.
 Interest. Interest will accrue and be payable in full on the Maturity Date.

 

4.  Payment. All payments must be made in lawful money of the United States of America at such place as the Holder may from
time to time designate in writing to the Company. Payment will be credited first to any accrued and unpaid interest then due and
payable, and the remainder will be applied to the principal. Prepayment of the principal, together with accrued and unpaid interest
thereon, may be made prior to the Maturity Date at any time without penalty. In the event any interest is paid on this Note that
is deemed to be in excess of the then legal maximum rate, then that portion of the interest payment representing an amount in
excess of the then legal maximum rate shall be deemed a payment of the principal and applied against the principal of this Note.

 

5.
Security Interest.

    	 	1	 

     

    

(a) Company hereby pledges, assigns and delivers to the Holder, and grants to the Holder, a lien upon and security interest in all
of the Company’s right, title and interest in and to all of the following property and assets of the Company, in each case
whether now owned or hereafter acquired or arising and wherever located (the “Company Collateral”): (i) all
accounts, deposit accounts, cash, cash equivalents, instruments, chattel paper, instruments, and money of the Company; (ii) all
contracts, copyrights, documents, equipment, fixtures, general intangibles, goods, inventory, patents, software, books and records
and other property included within the Purchased Assets as defined in the Asset Purchase Agreement; (iii) all accessions, additions,
attachments, improvements, modifications and upgrades to, replacements of and substitutions for any of the foregoing; and (iv)
any and all proceeds as defined in the Uniform Commercial Code. All terms in this Section that are not capitalized shall, unless
the context otherwise requires, have the meanings provided by the Uniform Commercial Code to the extent the same are used or defined
therein.

 

(b) Ember hereby pledges, assigns and delivers to the Holder, and grants to the Holder, a lien upon and security interest in all of
the Ember’s right, title and interest in and to all of the following property and assets of the Ember, in each case whether
now owned or hereafter acquired or arising and wherever located (the “Ember Collateral,” and together with
the Company Collateral, the “Collateral”): (i) all accounts, deposit accounts, cash, cash equivalents, instruments,
chattel paper, instruments, and money of the Ember; (ii) all contracts, copyrights, documents, equipment, fixtures, general intangibles,
goods, inventory, patents, software, books and records and other property included within the Purchased Assets as defined in the
Asset Purchase Agreement; (iii) all accessions, additions, attachments, improvements, modifications and upgrades to, replacements
of and substitutions for any of the foregoing; and (iv) any and all proceeds as defined in the Uniform Commercial Code. All terms
in this Section that are not capitalized shall, unless the context otherwise requires, have the meanings provided by the Uniform
Commercial Code to the extent the same are used or defined therein.

 

(c)
This Note and the Collateral shall secure the full and prompt payment, at any time and from time to time as and when due
(whether at the stated Maturity Date, by acceleration or otherwise), of all payment obligations of the Company or Ember under
this Note, including, without limitation, all principal of and interest on this Note, all fees, expenses, indemnities and
other amounts payable by the Company or Ember (including interest accruing after the filing of a petition or commencement of
a case by or with respect to the Company or Ember seeking relief under any applicable federal and state laws pertaining to
bankruptcy, reorganization, arrangement, moratorium, readjustment of debts, dissolution, liquidation or other debtor relief,
specifically including, without limitation, the Bankruptcy Code and any fraudulent transfer and fraudulent conveyance laws,
whether or not the claim for such interest is allowed in such proceeding), (collectively, the “Secured
Obligations”).

 

(d) If an Event of Default shall have occurred and be continuing, the Holder shall be entitled to exercise in respect of the Collateral
all of the rights, powers and remedies provided for herein or otherwise available under any law, in equity or otherwise, including
all rights and remedies of a secured party under the Uniform Commercial Code. Each of the Company and Ember, to the greatest extent
not prohibited by applicable law, hereby (i) agrees that it will not invoke, claim or assert the benefit of any rule of law or
statute now or hereafter in effect (including, without limitation, any right to prior notice or judicial hearing in connection
with the Holder’s possession, custody or disposition of any Collateral or any appraisal, valuation, stay, extension,

    	 	2	 

     

    

moratorium
or redemption law), or take or omit to take any other action, that would or could reasonably be expected to have the effect of
delaying, impeding or preventing the exercise of any rights and remedies in respect of the Collateral, the absolute sale of any
of the Collateral or the possession thereof by any purchaser at any sale thereof, and waives the benefit of all such laws and
further agrees that it will not hinder, delay or impede the execution of any power granted hereunder to the Holder, but that it
will permit the execution of every such power as though no such laws were in effect, (ii) waives all rights that it has or may
have under any rule of law or statute now existing or hereafter adopted to require the Holder to marshal any Collateral or other
assets in favor of the Company or Ember or any other party or against or in payment of any or all of the Secured Obligations,
(iii) waives all rights that it has or may have under any rule of law or statute now existing or hereafter adopted to demand,
presentment, protest, advertisement or notice of any kind (except notices expressly provided for herein), and (iv) waives all
rights of set-off, counterclaims or other defenses to the payment of this Note based upon or arising out of any actual or alleged
breach by the Holder or Stryker of any of their representations, warranties or covenants under the Asset Purchase Agreement or
any Ancillary Agreements (as defined therein) or any Losses (as defined therein) indemnifiable by Holder or Stryker under Section
7.02 of the Asset Purchase Agreement.

In
addition, each of the Company and Ember waives any and all rights of contribution or subrogation upon the sale or disposition
of all or any portion of the Collateral by the Holder.

 

6.  Events
of Default.The occurrence of any one or more of the following conditions or events will constitute an “Event
of Default”:

 

(a)  Failure
to Pay. The Company or Ember fails to pay the principal or accrued and unpaid interest due and payable under this Note when
due and payable pursuant to Section 2.

 

(b)  Breach
of Other Provisions. The Company or Ember breaches in any material respect any other provision of this Note, and such breach
continues uncured for a period of thirty (30) days after written notice of the breach has been delivered to the Company or Ember
by the Holder.

 

(c)
 Bankruptcy. (i) The Company or Ember commences proceedings seeking either its own bankruptcy or to be granted a suspension
of payments or any other proceeding under any bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors,
dissolution, insolvency or liquidation or similar law of any jurisdiction, whether now or hereafter in effect; (ii) any proceeding
described in clause (i) of this Section 6(c) is commenced or applied to be commenced against the Company or Ember, which
proceeding remains undismissed for a period of sixty (60) days; (iii) a custodian, trustee, administrator or similar official
is appointed under any applicable law described in clause (i) of this Section 6(c) with respect to the Company or Ember,
or such custodian, trustee, administrator or similar official takes charge of all or any substantial part of the property of the
Company or Ember; (iv) an adjudication is made that the Company or Ember is insolvent or bankrupt; (v) the Company or Ember makes
a general assignment for the benefit of its creditors; (vi) an attachment is made or taken with respect to a substantial part
of the assets of the Company or Ember, and such attachment is not removed or discharged within ninety (90) days after such attachment
is made or taken; or (vii) the Company or Ember takes any corporate or similar action for the purpose of effecting any of the
actions, orders or events described in the foregoing clauses of this Section 6(c).

    	 	3	 

     

    

(d) Dissolution
or Liquidation. Dissolution or liquidation of the business of the Company or Ember or suspension of the usual business of
the Company or Ember for a period of thirty (30) consecutive days.

 

(e)
Judgments. Any one or more money judgments, writs or warrants of attachment, executions or similar processes involving
an aggregate amount in excess of the $100,000 shall be entered or filed against the Company or Ember and the same shall not be
paid, dismissed, bonded, vacated, stayed or discharged within a period of thirty (30) days or in any event later than five days
prior to the date of any proposed sale of such property thereunder.

 

(f) Other Payment Defaults. The Company or Ember defaults with respect to its payment obligations under any indebtedness for
borrowed money in an aggregate amount in excess of $100,000.

 

7.  Remedies. Upon the occurrence of an Event of Default other than as described in Section 6(c), the Holder may declare
all amounts payable by the Company or Ember to the Holder under the terms of this Note immediately due and payable by the Company
or Ember to the Holder. Upon the occurrence of an Event of Default described in Section 6(c), all amounts payable by the
Company or Ember to the Holder under the terms of this Note will become automatically due and payable without presentment, protest
or demand of any kind. In addition to the foregoing remedies, the Holder will have all the rights, powers and remedies available
under the terms of this Note, under applicable law or otherwise. Notwithstanding the foregoing, in the event the Collateral is
insufficient security for the payment in full of the principal of and interest on this Note, the Holder shall not seek recourse
against the Company or its stockholders for the amount of any such deficiency.

 

8.  Expenses;
Costs of Collection. Each of the Company and Ember agrees to pay all costs and expenses of collection, including reasonable
attorneys’ fees and expenses, arising in connection with any enforcement action by the Holder in which the Holder prevails
on any of its rights under this Note whether by or through an attorney-at-law or in an action in bankruptcy, insolvency or other
judicial proceedings.

 

9.  Waiver
of Notice, etc. Each of the Company and Ember waives presentment for payment, demand, protest and notice of nonpayment or
dishonor and of protest, and of the exercise of any option under this Note or under the documents evidencing, securing or relating
to the indebtedness evidenced by this Note.

 

10.  Amendment;
Waiver; Assignment. No provision of this Note may be amended, waived or modified except by an instrument in writing signed
by, or on behalf of, the Company, Ember, and the Holder.

 

11.  Assignment.
Neither this Note nor any of the rights, interests or obligations hereunder may be assigned, by operation of law or otherwise,
in whole or in part, by the Company or Ember without the prior written consent of Holder. Subject to the foregoing, the rights
and obligations of the Company, Ember, and the Holder of this Note will be binding upon and inure to the benefit of the successors,
assigns, heirs, administrators and transferees of the parties.

    	 	4	 

     

    

12.  Notices.
Any notice, request or other communication required or permitted under this Note must be in writing and will be deemed to have
been duly given if personally delivered or mailed by registered or certified mail, postage prepaid, as follows:

 

	(a)            
     if to Holder:
	Stryker
        Corporation

        2825 Airview Blvd.

        Kalamazoo,
        MI 49002

        Attn: General Counsel

        Facsimile: (269)385-2066

        E-mail:
        michael.hutchinson@stryker.com

	 

        And

         

        Stryker
        Biotech L.L.C.

        One
        Broadway, 14th Floor

        Cambridge,
        MA 02142

        Attn:
        James Kemler, CEO

        E-mail:
        jamie.kemler@stryker.com

         

        with
        a copy to:

         

	Ropes
        & Gray LLP

        Prudential
        Tower

        800
        Boylston Street

        Boston,
        MA 02199-3600

	Facsimile:
    (617) 235-0398
	Email:
    james.wilton@ropesgray.com
	Telephone:
    (617) 951-7474
	Attention:  James
    M. Wilton
	(b)
                     if to Company:

	Mariel
        Therapeutics, Inc. 135 E. 57th St.

        24th
        Floor

        New
        York, NY 10022

	Email:
     jhernandez@marieltherapeutics.com
	Telephone:  646-829-1281
	Attention: Yosbani
    Joseph Hernandez, Executive Chairman
	 

        with
        a copy to:

 

    	 	5	 

     

    

	Thompson
                            Hine LLP

        335
        Madison Avenue, 12th Floor

	Facsimile:
    (212) 344-6101
	Email:
    Faith.Charles@ThompsonHine.com
	Telephone:
    (212) 908-3905
	Attention:
    Faith L. Charles
	(c)
                     if to Ember:

	Ember
        Therapeutics, Inc. 135 E. 57th St.

        24th
        Floor

        New
        York, NY 10022

	Email:
     jhernandez@marieltherapeutics.com
	Telephone:  646-829-1281
	Attention:
    Yosbani     Joseph Hernandez, Executive Chairman

 

Any
party hereto may by notice so given change its address for future notice hereunder. Notice will conclusively be deemed to have
been given when personally delivered or when deposited in the mail in the manner set forth above and will be deemed to have been
received when delivered.

 

13. 
Governing Law. This Note shall be governed by and construed in accordance with the laws of the State of New York, excluding
that body of law relating to conflict of laws.

 

14. 
Counterparts. This Note may be executed in any number of counterparts and by different parties on separate counterparts,
each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute
but one and the same Note. 

 

[Remainder
of the page intentionally left blank; signature page follows.]

    	 	6	 

     

    

  

IN
WITNESS WHEREOF, the each of the Company and Ember has caused this Note to be issued as of the date first above written.

 

	MARIEL
                            THERAPEUTICS, INC.

                             

                            By:
                            /s/ Yosbani Joseph Hernandez

                            Name:
                            Yosbani Joseph Hernandez

                            Title:
                            Executive Chairman

	 
	EMBER
        THERAPEUTICS, INC.

         

        By:
        /s/ Yosbani Joseph Hernandez

        Name:
        Yosbani Joseph Hernandez

        Title:
        Executive Chairman

	 
	STRYKER
        BIOTECH L.L.C.

         

        By:
        /s/ James Kemler

        Name:
        James Kemler

        Title:
        Chief Executive Officer

[Signature
page to Second Amended and Restated Secured Promissory Note.]

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]